SELLAS Life Sciences Group, Inc. announced results from its Phase 2 study of SLS009 in combination with AZA/VEN for R/R AML-MR patients. The study showed a 46% overall response rate, with a mOS of 8.9 months in the least pretreated cohort. No DLTs were observed, and the combination was well-tolerated. The company plans to expand the study to newly diagnosed AML patients with high-risk features in Q1 2026. These results demonstrate the potential of SLS009 to overcome resistance to VEN-based regimens and provide encouraging activity in heavily pretreated AML-MR patients, including those with adverse-risk mutations.

Read more at GlobeNewswire: SELLAS Life Sciences Presents Positive Phase 2 Data of